# BioNTech SE (BNTX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $86.92, market value $21.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BioNTech SE reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 7.4×**. Each dollar of revenue is priced at 7.4×.
- **Price / book: 1.0×**. The shares trade at 1.0× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 2.3%** (5-yr avg 11.7%). Free cash flow equals 2.3% of the market value, below its five-year average of 11.7%, so the shares are pricier on cash than usual.

## Profitability
- **Gross margin: 75.5%**. BioNTech SE keeps 75.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -46.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -39.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -5.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -10.6%**. Return on all capital, debt included, is -10.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -7.7%**. Each dollar of assets produces -7.7% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr -45.1%/yr, 5-yr 42.9%/yr). Revenue grew 4.3% over the last year, against 42.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -69.7%**. Earnings per share fell 69.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -72.3%/yr**. Free cash flow has compounded at -72.3% a year over three years.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 9.9×**. It would take 9.9 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 7.54** (quick 7.54). Current assets cover the next year's liabilities 7.54 times.
- **Altman Z-score: 6.65**. A Z-score of 6.65 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BioNTech SE does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (20 analysts). 20 analysts cover BioNTech SE; the consensus is buy, with an average price target of $116.59 (+34% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -15.8%** (YTD -8.1%, 3-mo -5.1%). The shares are down 15.8% over twelve months including dividends.
- **From 52-week high: -29.9%** (9.3% above the low). Trading 30% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 0.96** (volatility 47%). Beta of 0.96 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BNTX · Page: https://foliofundamentals.com/stocks/bntx

Not investment advice.